These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23200299)

  • 1. Breast cancer anxiety's associations with responses to a chemoprevention decision aid.
    Dillard AJ; Scherer L; Ubel PA; Smith DM; Zikmund-Fisher BJ; McClure JB; Greene S; Stark A; Fagerlin A
    Soc Sci Med; 2013 Jan; 77():13-9. PubMed ID: 23200299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
    Fagerlin A; Zikmund-Fisher BJ; Nair V; Derry HA; McClure JB; Greene S; Stark A; Hensley Alford S; Lantz P; Hayes DF; Wiese C; Claud Zweig S; Pitsch R; Jankovic A; Ubel PA
    Breast Cancer Res Treat; 2010 Feb; 119(3):613-20. PubMed ID: 19908143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
    Fagerlin A; Dillard AJ; Smith DM; Zikmund-Fisher BJ; Pitsch R; McClure JB; Greene S; Alford SH; Nair V; Hayes DF; Wiese C; Ubel PA
    Breast Cancer Res Treat; 2011 Jun; 127(3):681-8. PubMed ID: 21442198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affective forecasting and medication decision making in breast-cancer prevention.
    Hoerger M; Scherer LD; Fagerlin A
    Health Psychol; 2016 Jun; 35(6):594-603. PubMed ID: 26867042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    Korfage IJ; Fuhrel-Forbis A; Ubel PA; Zikmund-Fisher BJ; Greene SM; McClure JB; Smith DM; Alford SH; Fagerlin A
    Breast Cancer Res; 2013; 15(5):R74. PubMed ID: 24004815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Willingness to use tamoxifen to prevent breast cancer among diverse women.
    Kaplan CP; Kim SE; Wong ST; Sawaya GF; Walsh JM; Pérez-Stable EJ
    Breast Cancer Res Treat; 2012 May; 133(1):357-66. PubMed ID: 22315131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Snyder C; Seidel J; Hanna D; Lynch HT; Narod S
    Fam Cancer; 2005; 4(2):97-103. PubMed ID: 15951959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distinct role of comparative risk perceptions in a breast cancer prevention program.
    Dillard AJ; Ubel PA; Smith DM; Zikmund-Fisher BJ; Nair V; Derry HA; Zhang A; Pitsch RK; Alford SH; McClure JB; Fagerlin A
    Ann Behav Med; 2011 Oct; 42(2):262-8. PubMed ID: 21698518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How information about overdetection changes breast cancer screening decisions: a mediation analysis within a randomised controlled trial.
    Hersch J; McGeechan K; Barratt A; Jansen J; Irwig L; Jacklyn G; Houssami N; Dhillon H; McCaffery K
    BMJ Open; 2017 Oct; 7(10):e016246. PubMed ID: 28988168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).
    Holmberg C; Waters EA; Whitehouse K; Daly M; McCaskill-Stevens W
    Med Decis Making; 2015 Nov; 35(8):1010-22. PubMed ID: 26183166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
    Paterniti DA; Melnikow J; Nuovo J; Henderson S; DeGregorio M; Kuppermann M; Nease R
    Ethn Dis; 2005; 15(3):365-72. PubMed ID: 16108294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.
    Thorneloe RJ; Horne R; Side L; Wolf MS; Smith SG;
    Clin Breast Cancer; 2019 Feb; 19(1):e116-e126. PubMed ID: 30518498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy.
    Thorneloe RJ; Hall LH; Walter FM; Side L; Lloyd KE; Smith SG;
    Cancer Prev Res (Phila); 2020 Apr; 13(4):411-422. PubMed ID: 31988145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
    Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
    J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.
    Banegas MP; McClure JB; Barlow WE; Ubel PA; Smith DM; Zikmund-Fisher BJ; Greene SM; Fagerlin A
    Patient Educ Couns; 2013 Jun; 91(3):364-71. PubMed ID: 23395006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trait anxiety, symptom perceptions, and illness-related responses among women with breast cancer in remission during a tamoxifen clinical trial.
    Cameron LD; Leventhal H; Love RR
    Health Psychol; 1998 Sep; 17(5):459-69. PubMed ID: 9776005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.